Trial · NCT06333951
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Experiencing Dose Limiting Toxicities (DLT) | Up to approximately 21 days | |
| Primary | Number of Participants Experiencing Treatment Emergent Adverse Events (TEAE) | Up to approximately 3 years | TEAEs are any event that occurred after the participant received study treatment. Any clinically significant changes in vital signs, electrocardiograms, and clinical laboratory tests that occurred after study treatment administration were recorded as TEAEs. A serious TEAE is any untoward medical occurrence in a clinical study participant after first dose irrespective of a causal relationship with the study treatment(s) that resulted in death, was immediately life threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or another medically important serious event. |
| Primary | Number of Participants Experiencing Serious Adverse Events (SAE) | Up to approximately 3 years | An SAE is defined as any AE that results in death, is life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect or important medical events that do not meet the preceding criteria but based on appropriate medical judgment may jeopardize the participant or may require medical or surgical intervention to prevent any of the outcomes listed above. |
| Secondary | Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) | Up to approximately 3 years | |
| Secondary | Disease Control (DC) per RECIST v1.1 | Up to approximately 3 years | |
| Secondary | Duration of Response (DOR) per RECIST v1.1 | Up to approximately 3 years | |
| Secondary | Time to Response (TTR) per RECIST v1.1 | Up to approximately 3 years | |
| Secondary | Overall Survival (OS) per RECIST v1.1 | Up to approximately 3 years | |
| Secondary | Progression-free Survival (PFS) per RECIST v1.1 | Up to approximately 3 years | |
| Secondary | Maximum Plasma Concentration (Cmax) of Anvumetostat | Up to Day 1 of Cycle 5 (one cycle = 21 days) | |
| Secondary | Time to Maximum Plasma Concentration (tmax) of Anvumetostat | Up to Day 1 of Cycle 5 (one cycle = 21 days) | |
| Secondary | Area Under the Plasma Concentration-time Curve (AUC) of Anvumetostat | Up to Day 1 of Cycle 5 (one cycle = 21 days) | |
| Secondary | Intracranial objective response (IOR) per Response Assessment in Neuro Oncology Brain Metastases (RANO-BM ) | Up to approximately 3 years | |
| Secondary | Intracranial Disease Control (IDC) per RANO-BM | Up to approximately 3 years | |
| Secondary | Intracranial Duration of Response (IDOR) per RANO-BM | Up to approximately 3 years | |
| Secondary | Time to Intracranial Radiation Therapy per RANO-BM | Up to approximately 3 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06333951/registered